NasdaqCM - Nasdaq Real Time Price • USD
Oramed Pharmaceuticals Inc. (ORMP)
As of 10:03 AM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 2 | -- |
Avg. Estimate | 0.02 | -0.02 | -0.26 | 0 |
Low Estimate | 0.02 | -0.02 | -0.41 | 0 |
High Estimate | 0.02 | -0.02 | -0.11 | 0 |
Year Ago EPS | -0.08 | -0.03 | 0.14 | -0.26 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 2 | 1 |
Avg. Estimate | 500k | 500k | 1.3M | -- |
Low Estimate | 500k | 500k | 600k | -- |
High Estimate | 500k | 500k | 2M | -- |
Year Ago Sales | 750k | 674k | 1.34M | 1.3M |
Sales Growth (year/est) | -33.30% | -25.80% | -3.00% | -- |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.26 | -0.1 | -0.08 | -0.12 |
EPS Actual | -0.08 | -0.03 | -0.08 | 0.33 |
Difference | 0.18 | 0.07 | 0 | 0.45 |
Surprise % | 69.20% | 70.00% | 0.00% | 375.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.02 | -0.02 | -0.26 | 0 |
7 Days Ago | 0.02 | -0.02 | -0.26 | -1.08 |
30 Days Ago | 0.02 | -0.02 | -0.26 | -1.08 |
60 Days Ago | 0.02 | -0.02 | -0.26 | -1.08 |
90 Days Ago | 0.02 | -0.02 | -0.26 | -1.08 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | ORMP | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 125.00% | -- | -- | 1.50% |
Next Qtr. | 33.30% | -- | -- | 12.10% |
Current Year | -285.70% | -- | -- | 4.40% |
Next Year | -- | -- | -- | 13.20% |
Next 5 Years (per annum) | -- | -- | -- | 10.97% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | Canaccord Genuity: Hold to Hold | 5/17/2023 |
Downgrade | HC Wainwright & Co.: Buy to Neutral | 1/17/2023 |
Downgrade | Canaccord Genuity: Buy to Hold | 1/12/2023 |
Maintains | Aegis Capital: Buy | 5/16/2022 |
Initiated | Cantor Fitzgerald: Overweight | 2/18/2022 |
Maintains | HC Wainwright & Co.: Buy | 11/30/2021 |
Related Tickers
ENLV Enlivex Therapeutics Ltd.
1.4899
+2.75%
EVGN Evogene Ltd.
0.6400
-2.65%
BLRX BioLineRx Ltd.
0.5776
+0.40%
IFRX InflaRx N.V.
1.3508
-2.82%
EVGN.TA Evogene Ltd.
256.20
-1.16%
PLUR Pluri Inc.
5.34
+1.96%
CGEN Compugen Ltd.
1.8850
-0.79%
LCTX Lineage Cell Therapeutics, Inc.
1.1250
+1.35%
BONS.TA Bonus BioGroup Ltd.
16.90
0.00%
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0800
+3.36%